2025/01/16
BEIJING--Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Judicial Committee of t
The first phase III clinical trial on a multivalent HFMD vaccine in the worldDecember 13, 2024, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a
2024/12/16
On July 20, 2024, Sinovac Biotech Ltd. ("SINOVAC" or the "Company") and the China Foundation for Hepatitis Prevention and Control successfully jointly held the "Hepatitis A Pr
2024/07/29
Beijing, China – June 18, 2024 – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that its PROV
2024/06/18
The content is intended for use by media professionals
These images may be downloaded for non-commercial use and for purposes such as news reporting or research. Images may not be modified and must display the following copyright language: Copyright © SINOVAC Biotech Ltd. All rights reserved.
Learn more about SINOVAC copyright and trademark policies.
Media Contacts: pr@sinovac.com
EN
